GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution
Rapid weight loss can lead to issues with bone quality, particularly in older adults.
Stock Taper 
GLP
$47.96
▲ UP 1.85% (0.87)
KEY STATISTICS
Market Cap$1.62 B
52w High$54.29
52w Low$39.58
Dividend Yield6.19%
FrequencyQuarterly
P/E9.77
Volume63.52K
Shares Out.33.85M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Eric S. Slifka
ABOUT
SECTOR
Energy
WENT PUBLIC
October 4, 2005
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
4,700
PRICE TARGET
Target High$46.00
Target Low$46.00
Target Median$46.00
Target Consensus$46.00
UPCOMING EARNINGS
DateNov 6, 2026
DayFriday
Rev. Est.$7.41B
NOV
6
FRI
ETFS HOLDING THIS STOCK
ETFS HOLDING
18
LISTED HERE
10
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
56.43%
HOLDERS
156
TOP 8 OF 156 · RANKED BY POSITION SIZE
PRICE
$47.96 ▲ UP 1.85% (+$0.87)About Global Partners LP
https://www.globalp.com ↗Global Partners LP is a Massachusetts-based company involved in the purchasing, selling, transportation, and distribution of gasoline, fuels, and crude oil across the U.S. Northeast, Mid-Atlantic, and mid-continent regions.
INDUSTRY
Oil & Gas Midstream
A PRODUCT GLOBAL PARTNERS LP IS KNOWN FOR
Alltown Fresh
Alltown Fresh, the flagship convenience store of Global Partners LP, offers fresh, made-to-order food, healthy snacks, and locally sourced products to elevate the retail experience with healthier, higher-quality options.
Global Partners LP in 2025
SENTIMENT: − NEGATIVE
EARNINGS · NOVEMBER 2025
Global Partners LP Stock Drops After Significantly Missing Q3 2025 Earnings and Revenue Forecasts
On November 7, 2025, Global Partners LP reported third-quarter financial results that fell substantially short of analyst expectations. The company announced earnings per share of $0.66, missing the consensus estimate of around $0.85-$1.10, and revenue of $4.69 billion also missed forecasts. [3, 4, 5] This resulted in a notable negative reaction from investors and put the company in the spotlight.
MARKET EXPANSION · Q3 2025 · IN PROGRESS
Global Partners LP Expands into Houston Marine Fuel Market, Signaling Geographic Diversification
In a notable strategic move, Global Partners LP announced its expansion into the Houston marine fuel market. This decision marks a significant geographic diversification for the company, extending its operational footprint into a key U.S. Gulf States energy hub and complementing its established presence in the Northeast and Mid-Atlantic.
Latest News
EARLIER COVERAGE
Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform
Milestone advances portfolio company's intellectual-property foundation for InsuTab™ and BuccaGLP™, supported by an exclusive worldwide UBC licence and Hydreight's previously disclosed U.S. distribution rights VANCOUVER, BC, Oct. 8, 2026 /PRNewswire/ -- Victory Square Technologies Inc. ("Victory Square," "VST" or the "Company") (CSE: VST) (OTCQX: VSQTF) (FWB: 6F6) today announced that portfolio company Insu Therapeutics Inc. ("Insu") has received a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for a patent application covering its buccal peptide-delivery technology. The allowance advances the intellectual-property foundation behind InsuTab™, Insu's investigational buccal insulin formulation, and BuccaGLP™, its investigational buccal semaglutide formulation.
Zacks Industry Outlook Western Midstream, Global Partners and NGL Energy Partners
Western Midstream, Global Partners and NGL Energy Partners have been highlighted in this Industry Outlook article.
Refining & Marketing MLP Industry Shines: 3 Stocks to Watch
Following a careful analysis of the Zacks Oil and Gas - Refining & Marketing MLP industry, we advise keeping an eye on three stocks: WES, GLP and NGL.
Eli Lilly: Buy The GLP-1 Growth Premium
Eli Lilly is building a dominant obesity and diabetes treatment portfolio, positioning itself as a high-growth, premium-valued pharmaceutical company. LLY's tirzepatide-based products, Mounjaro and Zepbound, drive nearly $15 billion in revenue with 91% and 46% YoY growth, respectively. I assign a buy rating to LLY, justifying its 25x EV/EBITDA premium by 20%+ annual sales growth and robust free cash flow expansion.
FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body
New approach proposes an alternative to repeated injections HOUSTON, Oct. 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today that it has filed a U.S. patent application covering a new cell-based technology designed to continuously produce peptides such as GLP-1, GIP and GLP-2 inside the body. Today, popular GLP-1 medicines used for weight loss and diabetes generally require patients to take regular weekly injections or daily pills.
Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
Novo Nordisk rose dramatically because investors were excited after it launched the first GLP-1 weight-loss drug. The company lost the lead in the emerging GLP-1 space to Eli Lilly.
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034 Novo announces additional weight-loss in patients switching from injected to oral delivery
Critical Analysis: Global Partners (NYSE:GLP) and EQT (NYSE:EQT)
EQT (NYSE: EQT - Get Free Report) and Global Partners (NYSE: GLP - Get Free Report) are both energy companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Earnings and Valuation This table compares EQT and Global
MichaelAaron Flicker on How GLP-1s Change Food Industry & Household Dynamics
MichaelAaron Flicker, founder and CEO of XenoPsi Ventures, walks through the impact that GLP-1 drugs are having on consumer behavior and how some of the top consumer food brands are responding. Flicker examines how GLP-1 users impact the behavior of entire households, the changing dynamic of the restaurant experience and where GLP-1 users are spending outside of grocery stores and eating out.
SHOWING 2–10 OF 15
RATINGS SNAPSHOT
Overall rating: B
Discounted Cash Flow1
Return On Equity5
Return On Assets5
Debt To Equity1
Price To Earnings3
Price To Book2
Overall Score3
MOST RECENT ANALYST GRADES
GRADE SUMMARY
HOLD 1
1 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 EFXT | $23.68 | COMPARE |
 DNOW | $15.56 | COMPARE |
 LPG | $58.20 | COMPARE |
 INVX | $27.48 | COMPARE |
 WKC | $37.38 | COMPARE |
 XPRO | $16.29 | COMPARE |
 NEXT | $6.79 | COMPARE |
 FLNG | $31.52 | COMPARE |
TRADES BY CONGRESS
HOUSE TRADES
Mark Dr Green
Sale (Full)
2021-10-06
Mark E. Green
Sale (Full)
2021-10-06
INSIDER TRADES
★
OTHER: GENERAL PARTNER
Global GP LLC
Purchase · 5.0K shares
2026-09-21
★
OTHER: GENERAL PARTNER
Global GP LLC
Purchase · 5.0K shares
2026-09-16
★
OTHER: GENERAL PARTNER
Global GP LLC
Purchase · 5.0K shares
2026-06-18
★
OTHER: GENERAL PARTNER
Global GP LLC
Purchase · 5.0K shares
2026-06-15